Status:
COMPLETED
Dose Finding Confirmation of Atazanavir With Ritonavir and Efavirenz (ATV/RTV + EFV) in Healthy Subjects
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
HIV Infections
Protease Inhibitor
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to assess the exposure of Atazanavir 400 mg with Ritonavir 100 mg and with Efavirenz 600 mg compared to Atazanavir 300 mg with 100 mg without Efavirenz in Healthy Subjects
Eligibility Criteria
Inclusion
- BMI 18-30
- Men and women who are not of childbearing potential, ages 18-50 years, inclusive
Exclusion
- History of seizures or other central nervous system disorders (including migraine headaches)
- history of diagnosed mental illness or suicidal tendencies
- positive screening for Hep B surface antigen
- Hep C antibody
- HIV-1, -2
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
End Date :
September 1 2006
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT00357188
Start Date
July 1 2006
End Date
September 1 2006
Last Update
April 8 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Hamilton, New Jersey, United States